Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@article{Li2010DesignOA,
  title={Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.},
  author={Xiangming Li and Masakazu Fujio and Masakazu Imamura and Douglass Wu and Sandhya Vasan and C. -H. Wong and David D. Ho and Moriya Tsuji},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2010},
  volume={107 29},
  pages={13010-5}
}
The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown to bind CD1d molecules to activate invariant natural killer T (iNKT) cells, and subsequently induce activation of various immune-competent cells, including dendritic cells, thereby providing a significant adjuvant effect for various vaccines. However, in phase I clinical trials, alpha-GalCer was shown to display only marginal biological activity. In our search for a glycolipid that can exert more potent stimulatory activity… CONTINUE READING